Offin et al. [45] divided NSCLC patients, who harbored EGFR mutations and were treated with EGFR-TKIs, into low (TMB ≤ 2.83 mutations/Mb), intermediate (2.84 < TMB < 4.85 mutations/Mb), and high (TMB > 4.85 mutations/Mb) groups. Here, EGFR is linked to non-small cell lung carcinoma.